Glucokinase Activator in Monogenic Diabetes

Phase 2 Recruiting 44 enrolled Chinese University of Hong Kong

RandomizedCrossoverDouble-blindTreatment

Summary

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

Timeline

Start: 2025-04-30
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dorzagliatin	Small molecule	50 mg	—

Glucokinase Activator in Monogenic Diabetes

Summary

Timeline

Drugs

Indications